News

Latest news

Hide mandatory notifications of trade
  • Mandatory notification of trade

    Financial .2012

    Oslo, 18.08.2012 - Jerome Zeldis, Board member of Bionor Pharma ASA, has yesterday purchased 100,000 Bionor shares at a price of NOK 3.45 per share.

  • GLOBVAC Awards US$1.7 Million for research on Vacc-4x

    Financial .2012

    GLOBVAC Awards Bionor Pharma US$1.7 Million to Advance Research Towards an HIV Cure Using Vaccine Vacc-4x. Award Represents Vital Step to Research Future Solutions for People Living with HIV.

  • GLOBVAC gir 10,5 mill til vaksineforskning på Vacc-4x

    Financial .2012

    GLOBVAC har tildelt Bionor Pharma NOK 10,48 mill. for å videreføre forskningen på en kur mot hiv ved hjelp av vaksinen Vacc-4x.Tildelingen representerer et viktig skritt innen forskning på fremtidens behandling for mennesker som lever med hiv.

  • Mandatory Notification of trade

    Financial .2012

    Oslo, 15.06.2012 - CEO of Bionor Pharma ASA, Steen Krøyer, has yesterday, as part of the Company's Private Placement, purchased 117,200 Bionor shares at a price of NOK 3.20 per share.

  • Mandatory Notification of trade

    Financial .2012

    Oslo, 15.06.2012 - Marianne Furru, Board member of Bionor Pharma ASA, has yesterday, as part of the Company's Private Placement, purchased 117,200 Bionor shares through the company Fular AS at a price of NOK 3.20 per share.

  • Meldepliktig handel

    Financial .2012

    Oslo,15.06.2012 - Marianne Furru, styremedlem i Bionor Pharma ASA har i dag, som ledd i Selskapets rettede emisjon, kjøpt via selskapet Fular AS 117 200 aksjer i Bionor Pharma ASA til en pris på NOK 3,20.

  • Bionor Pharma ASA - Successfully Completes Private Placement

    Financial .2012

    Reference is made to the stock exchange notice published by Bionor Pharma ASA (“Bionor” or the “Company”) on 14 June 2012 regarding the contemplated private placement of new shares (the “Private Placement”). The Board of Directors of Bionor is pleased to announce that the Private Placement has been successfully subscribed for and allocated. The transaction was oversubscribed.

  • Bionor Pharma ASA – Contemplated Private Placement

    Financial .2012

    Bionor Pharma (“Bionor” or the “Company”) has engaged SEB Enskilda (the "Manager") to advise on and effect a contemplated private placement (the “Private Placement”) of up to 18,000,000 new shares directed towards investors in Norway and internationally.

  • Minutes from the Annual General Meeting of Bionor Pharma ASA

    Financial .2012

    Oslo 11.05.2012 - Bionor Pharma ASA's Annual General Meeting was held today. All proposed resolutions in the notice to the meeting were approved by the shareholders.

  • New Board after Annual General Meeting

    Financial .2012

    Oslo 11.05.2012 - Bionor Pharma`s Shareholders Voted Industry Experts Steen Krøyer, Jerry Zeldis and Benedicte Fossum to its Board of Directors at Annual General Meeting